Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

This trial tests EX103, a new antibody drug targeting CD20, in people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has relapsed or stopped responding after at least 2 prior treatment regimens. **You may be eligible if...** - You are 18 or older with CD20-positive non-Hodgkin lymphoma confirmed at initial diagnosis - Your lymphoma has relapsed or not responded after at least 2 prior lines of treatment - No suitable treatment options are available - For the expansion phase: you may have DLBCL, follicular lymphoma, or other CD20-positive NHL subtypes depending on the cohort **You may NOT be eligible if...** - Your cancer has lost CD20 expression after prior rituximab treatment - You have uncontrolled serious infections (HIV, active hepatitis B or C) - You are pregnant or breastfeeding - You have a known allergy to the study drug - You have active CNS lymphoma Talk to your doctor to see if this trial is right for you.